CNTO 7160

Drug Profile

CNTO 7160

Latest Information Update: 29 Jul 2016

Price : $50

At a glance

  • Originator Janssen Research & Development
  • Class Antiasthmatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Atopic dermatitis

Most Recent Events

  • 27 Jul 2016 CNTO 7160 licensed to GlaxoSmithKline worldwide
  • 31 Aug 2014 Phase-I clinical trials in Atopic dermatitis in Belgium (IV)
  • 31 Aug 2014 Phase-I clinical trials in Asthma in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top